Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.53T
24h Vol:
$11.03B
Dominance:
MSFT:5.18%
Stocklytics Platform
BETA
Instrument logo  GILD

Gilead Sciences Inc

GILD
73 / 100
S&P500
$72.25arrow_drop_down-0.08%-$0.06
Key Stats
Open$72.28
Prev. Close$72.10
EPS4.5
Dividend$3.00
Next Earnings DateJun 27, 2024
Dividend Yield %4.26%
Market Cap$90.08B
PE Ratio16.07
LOWHIGH
Day Range72.04
72.66
52 Week Range71.37
87.87
Ratios
P/B Ratio3.94
Revenue$27.11B
Operating M. %35.65%
Earnings$5.66B
Earnings Growth %24.07%
EBITDA Margin %44.36%
ROE %25.54%
EPS4.5
Fundamentals
RPS$21.73
Gross Profit$27.11B
EBITDA$11.70B
Total Debt$25.65B
P/S Ratio3.3x
Enterprise to EBITDA10.32
Profit Margin20.89%
ROA9.31%
Debt/Equity Ratio1.13%
Payout Ratio42.90%
Industry average yield3.04%
Last Dividend pay dateMar 28, 2024
Dividend per share$3.00
Dividend yield forecast0.04%

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

GILDarrow_drop_down-0.83%
US Healthcare Sectorarrow_drop_down-0.30%
US Marketarrow_drop_down-0.28%
GILD / Market
GILD lose to the US Market which returned -0.28% over the last twenty four hours.
GILD / Healthcare Sector
GILD lose to the US Healthcare sector which returned -0.30% over the last twenty four hours.

Gilead Sciences Inc (GILD) Statistics

Gilead Sciences Inc, also known as GILD, is a leading biotechnology company with a strong focus on research and development of innovative therapies in the fields of HIV, hepatitis, and other viral diseases. The company is known for its groundbreaking antiviral drugs, including the widely used HIV drugs Truvada and Atripla. Gilead Sciences Inc has a market capitalization of over $80 billion, making it one of the largest biotech companies in the world.

When it comes to valuation metrics, Gilead Sciences Inc has a price-to-earnings ratio (P/E) of 10.56, which indicates that the stock is currently undervalued compared to its earnings. The company also has a price-to-sales ratio (P/S) of 3.67, suggesting that investors are willing to pay a premium for its revenue. In terms of fundamentals, Gilead Sciences Inc has a strong balance sheet with a total debt of $27.2 billion and a gross profit of $24.7 billion. The company's profit margin stands at 43.89%, indicating that it is highly efficient in turning revenue into profit.

add Gilead Sciences Inc to watchlist

Keep an eye on Gilead Sciences Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How much debt does Gilead Sciences Inc (GILD) have?

Gilead Sciences Inc (GILD) has a total debt of $25.66B. The net debt, which accounts for cash and cash equivalents against the total debt, is -$6.08B.

question_mark
How has Gilead Sciences Inc (GILD) stock's performance compared to its sector and the market over the past year?

Over the past year, Gilead Sciences Inc (GILD) has experienced a price change of -9.46%. Compared to the Healthcare sector, which saw a change of 33.67%, Gilead Sciences Inc has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 38.63%, it has fallen short of the market average. This comparison highlights Gilead Sciences Inc's performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Gilead Sciences Inc (GILD) stock?

The PE (Price to Earnings) ratio of Gilead Sciences Inc (GILD) is currently 16.02. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

question_mark
What is the EPS of Gilead Sciences Inc (GILD) stock?

The Earnings Per Share (EPS) for Gilead Sciences Inc (GILD), calculated on a diluted basis, is $4.5. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Gilead Sciences Inc (GILD) stock?

The operating margin for Gilead Sciences Inc (GILD) is 35.65%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Gilead Sciences Inc (GILD) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Gilead Sciences Inc (GILD) is $11.7B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.